CD58 Emerges as a Central Player in How Tumors Evade Immune Attack and Resist Therapy
A new review in Molecular Cancer details how loss of the immune synapse molecule CD58 drives tumor immune evasion and ...
Tag: Tumor Immune Evasion
CRISPR Screens Reveal DNMT3A’s Dual Role in Tumor Immune Evasion
In vivo CRISPR screens reveal that the epigenetic enzyme DNMT3A can both preserve and suppress tumor immune visibility, reshaping how ...
Scientists Map How Tumours Push Immune Cells Into Exhaustion
A review in Experimental & Molecular Medicine examines how chronic antigen exposure and a hostile tumour microenvironment reprogram T cells ...
Where does the immune pressure go? New framework explains immunotherapy resistance
A new Molecular Cancer review proposes immune-pressure redistribution as a unifying framework explaining why patients resist PD-1/PD-L1 blockade and how ...
Hidden Protein Signals Decide Why Immunotherapy Fails in Gut Cancers
A new review maps how secreted protein circuits in gastrointestinal tumours govern immune recruitment, suppression and response to checkpoint immunotherapy.
Mogrosides regulate tumor metabolism and immune response, revealing dual anticancer mechanism
The monk fruit, a small green gourd native to the mountainous forests of Guangxi province in southern China, has been ...
Small Cell Lung Cancer Relies on Targetable Nonsense-Mediated Decay for Immune Control
A Hidden RNA-Decay System May Be the Achilles’ Heel of Small-Cell Lung Cancer Small-cell lung cancer, one of the most ...
USP30-AS1 micropeptide drives tumor growth by suppressing macrophage cGAS–STING interferon signaling
Immune checkpoint inhibitors have transformed cancer treatment by releasing molecular brakes that otherwise restrain T cells, yet their benefits remain ...
Engineered macrophages reprogram tumor microenvironments, boosting antitumor immunity with IL-10–TLR9 switches
Cancer immunotherapy has transformed treatment for some patients, yet many solid tumors remain protected by a hostile biological environment that ...
Early Trial Tests Ontorpacept Plus Doxorubicin for Advanced Leiomyosarcoma
A new Phase 1/2 clinical study is testing whether an immune-targeting drug can make chemotherapy more effective against high-grade leiomyosarcoma, ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!